share_log

Heart Test Laboratories | 10-Q: Q3 2024 Earnings Report

Heart Test Laboratories | 10-Q: Q3 2024 Earnings Report

Heart Test Laboratories | 10-Q：2024財年三季報
美股SEC公告 ·  2024/03/14 16:14

Moomoo AI 已提取核心訊息

Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
醫療技術公司Heart Test Laboratories在其最新的季度報告中未提供具體的財務表現指標，如營業收入、營業利潤、淨利潤或股份瑕疵收益率等。然而，該公司已披露股票期權的股票補償，由2023年1月31日結束的9個月中的$149,153增加到2024年同期的$326,578。推遲的稅款資產也已報告，2024年1月31日的淨營業虧損仍達5200萬美元，較上年增長了4600萬美元。該公司已經與多個機構簽訂了重大的業務發展協議，包括與羅格斯大學的多年合作以及與Mount Sinai簽訂的AI心血管算法多項明確授權協議。Heart Test Laboratories計劃爲MyoVista設備提交510(k) FDA申請，併力爭在2024年日曆年內獲得清關。該公司還在各個地區獲得了專利許可並簽訂了支持其業務的金融協議，包括與Maxim Group LLC的股權分銷協議。
醫療技術公司Heart Test Laboratories在其最新的季度報告中未提供具體的財務表現指標，如營業收入、營業利潤、淨利潤或股份瑕疵收益率等。然而，該公司已披露股票期權的股票補償，由2023年1月31日結束的9個月中的$149,153增加到2024年同期的$326,578。推遲的稅款資產也已報告，2024年1月31日的淨營業虧損仍達5200萬美元，較上年增長了4600萬美元。該公司已經與多個機構簽訂了重大的業務發展協議，包括與羅格斯大學的多年合作以及與Mount Sinai簽訂的AI心血管算法多項明確授權協議。Heart Test Laboratories計劃爲MyoVista設備提交510(k) FDA申請，併力爭在2024年日曆年內獲得清關。該公司還在各個地區獲得了專利許可並簽訂了支持其業務的金融協議，包括與Maxim Group LLC的股權分銷協議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    PAVmed
    PAVMZ
    -- 0.0129
    QT Imaging
    QTI
    -- 0.469
    Sera Prognostics
    SERA
    -- 8.320
    Pacific Biosciences of California
    PACB
    -- 2.100
    Quipt Home Medical
    QIPT
    -- 3.090

    解鎖榜首股票

    熱門討論
    特朗普2.0時代倒計時！全球股市的下一個風口？
    特朗普即將重返政治舞台！他提出的“美國優先”關稅政策、加密貨幣政策以及對科技行業的影響，已成為市場關注的焦點。在此背景下，加密貨幣、特斯拉、AI板塊的未來走勢值得關注。 🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？ 展开
    賣盤分析師 - 川普的第一天
    查看更多